


| | Onset of Action | Peak (h) | Duration of Action (h) |
|--|-----------------|----------|------------------------|
| Pharmacokinetics of Human Insulin and Analogues | | | |
| Human Insulin (Injected) | | | |
| Regular | 0.5-1 h | 2-4 | 6-8 |
| NPH | 2-4 h | 4-6 | 12-16 |
| Lente | 2-4 h | 4-8 | 12-18 |
| Human Insulin (Inhaled) | | | |
| Exubera | 12-24 min | 0.5-1.5 | 6-8 |
| Analog | | | |
| Lispro | 5-15 min | 1-2 | 4-5 |
| Aspart | 5-15 min | 1-2 | 4-5 |
| Glulisine | 5-15 min | 1-2 | 4-5 |
| Glargine | 2-4 h | Flat | ~24 |
| Detemir | 2-3 h | 6-10 | 14-16 |

The time course of action of any insulin may vary between individuals, or at different times in the same individual. Consequently, the data presented should be considered only as a general guideline.

Action Profiles of Traditional Insulin Formulations



REFERENCES

1. Skyler JS. Insulin treatment. In: Lebovitz HE, ed. *Therapy for Diabetes Mellitus and Related Disorders*. 3rd ed. Clinical Education Series. Alexandria, VA: American Diabetes Association. 1998:186-203.
2. Burge MR, Schade DS. Insulins. *Endocrinol Metab Clin North Am*. 1997;26:575-598.
3. Danne T, Lupke K, Walte K, Von Schuetz W, Gail MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. *Diabetes*
4. Barlocco D. Insulin glulisine. Aventis Pharma. *Curr Opin Invest Drugs*. 2003;4:1240-1244.
5. Cefalu WT, Waldman S, Ryder S. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents. *Clin Pharmacol Ther*. 2007;81(5):636-649.
6. Edelman, SV, Morello, CM. Strategies for insulin therapy in type 2 diabetes. *South Med J*. 2005;98:363-371.
7. Exubera prescribing information. *Physicians' Desk Reference* 61st edn. Thomson PDR: Montvale, NJ. 2007:2524-
8. Levemir prescribing information. *Physicians' Desk Reference* 61st edn. Thomson PDR: Montvale, NJ. 2007:2320-